PROVIDENCE – Maternova Research, a newly formed nonprofit arm of the award winning Maternova, recently announced that Merck has granted project funding for pilot studies of a new global health diagnostic technology. The funds will be used to conduct a official product feasibility study featuring the new uChek device.
Manufactured by Biosense Technologies Private Limited in India, the uChek device provides critical care in low-resource settings for expectant mothers and patients. The device is a smartphone based portable diagnostic system that can perform tests ranging from routine urinalysis to more specialized urine and blood tests including a blood sugar test.
Most importantly for maternal health, the uChek allows healthcare workers to track a set biomarkers in a urine sample, including protein, glucose, leukocytes, nitrites and urobilinogen. The presence of protein in a pregnant woman’s urine when accompanied by high blood pressure is one of the earliest signs of preeclampsia. Eclampsia and pre-eclampsia represent a major cause of maternal mortality and morbidity globally. Other conditions such as gestational diabetes and pernicious anemia are indicated in urine samples.
Each year, millions of women lack even basic antenatal care during their pregnancy. Simplified procedures combined with innovative design can significantly reduce the occurrence of life threatening complications for both mom and baby.